Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

Katsuya Suzuki, Hideto Kameda, Koichi Amano, Hayato Nagasawa, Hirofumi Takei, Eiko Nishi, Ayumi Okuyama, Kensei Tsuzaka, Tsutomu Takeuchi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N = 21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.

Original languageEnglish
Pages (from-to)757-763
Number of pages7
JournalRheumatology International
Volume31
Issue number6
DOIs
Publication statusPublished - 2011 Jun

Fingerprint

Tacrolimus
Systemic Lupus Erythematosus
Prospective Studies
Safety
Therapeutics
Nephritis
Arthritis
Oral Administration
Adrenal Cortex Hormones
Skin

Keywords

  • Systemic lupus erythematosus
  • T cell
  • Tacrolimus

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. / Suzuki, Katsuya; Kameda, Hideto; Amano, Koichi; Nagasawa, Hayato; Takei, Hirofumi; Nishi, Eiko; Okuyama, Ayumi; Tsuzaka, Kensei; Takeuchi, Tsutomu.

In: Rheumatology International, Vol. 31, No. 6, 06.2011, p. 757-763.

Research output: Contribution to journalArticle

Suzuki, Katsuya ; Kameda, Hideto ; Amano, Koichi ; Nagasawa, Hayato ; Takei, Hirofumi ; Nishi, Eiko ; Okuyama, Ayumi ; Tsuzaka, Kensei ; Takeuchi, Tsutomu. / Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. In: Rheumatology International. 2011 ; Vol. 31, No. 6. pp. 757-763.
@article{7c56209ce0c44909b481cfc7d1431428,
title = "Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus",
abstract = "The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N = 21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8{\%}) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.",
keywords = "Systemic lupus erythematosus, T cell, Tacrolimus",
author = "Katsuya Suzuki and Hideto Kameda and Koichi Amano and Hayato Nagasawa and Hirofumi Takei and Eiko Nishi and Ayumi Okuyama and Kensei Tsuzaka and Tsutomu Takeuchi",
year = "2011",
month = "6",
doi = "10.1007/s00296-010-1366-9",
language = "English",
volume = "31",
pages = "757--763",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

AU - Suzuki, Katsuya

AU - Kameda, Hideto

AU - Amano, Koichi

AU - Nagasawa, Hayato

AU - Takei, Hirofumi

AU - Nishi, Eiko

AU - Okuyama, Ayumi

AU - Tsuzaka, Kensei

AU - Takeuchi, Tsutomu

PY - 2011/6

Y1 - 2011/6

N2 - The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N = 21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.

AB - The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1-6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N = 21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.

KW - Systemic lupus erythematosus

KW - T cell

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=79959999365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959999365&partnerID=8YFLogxK

U2 - 10.1007/s00296-010-1366-9

DO - 10.1007/s00296-010-1366-9

M3 - Article

VL - 31

SP - 757

EP - 763

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 6

ER -